At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Letermovirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Letermovir for Cytomegalovirus Prophylaxis in Patients With Hematological Malignancies Treated With Alemtuzumab
Ohio State University Comprehensive Cancer Center·interventional·Posted Mar 18, 2020·Updated Feb 28, 2025
In Brief
A Phase 2 clinical trial evaluating Letermovir for B-Cell Prolymphocytic Leukemia and 5 related conditions. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic Leukemia
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartSep 2020
Primary CompletionNov 2023
Study CompletionApr 2024
TodayJul 2026
First PostedMar 18, 2020
Enrollment StartSep 15, 2020
Primary CompletionNov 24, 2023
Study CompletionApr 9, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 6.3 years ago
Interventions
Letermovirdrug
Given PO